Good story though slanted to the negative in regards to actually wanting to know if you have it or not. But, great to finally see Amarantus mentioned in a widely read financial site (even though it won't be in the published magazine though I'll be on the look out for it as Forbes SHOULD do an specific story on AMBS imo.).